

1 **Plasma Markers of Disrupted Gut Permeability in Severe COVID-19**  
2 **Patients**

3 **Authors:** Leila B. Giron<sup>1</sup>, Harsh Dweep<sup>1</sup>, Xiangfan Yin<sup>1</sup>, Han Wang<sup>1</sup>, Mohammad Damra<sup>1</sup>, Aaron R.  
4 Goldman<sup>1</sup>, Nicole Gorman<sup>1</sup>, Clovis S. Palmer<sup>2,3</sup>, Hsin-Yao Tang<sup>1</sup>, Maliha W. Shaikh<sup>4</sup>, Christopher B.  
5 Forsyth<sup>4</sup>, Robert A. Balk,<sup>4</sup> Netanel F Zilberstein,<sup>4</sup> Qin Liu<sup>1</sup>, Andrew Kossenkov<sup>1</sup>, Ali Keshavarzian<sup>4</sup>,  
6 Alan Landay<sup>4</sup>, Mohamed Abdel-Mohsen<sup>1\*</sup>

7

8 **Affiliations:** <sup>1</sup>The Wistar Institute, Philadelphia, PA, 19104, USA; <sup>2</sup>The Burnet Institute, Melbourne,  
9 Victoria, 3004, Australia; <sup>3</sup>Department of Infectious Diseases, Monash University, Melbourne, Victoria,  
10 3004, Australia; <sup>4</sup>Rush University, Chicago, IL, 60612, USA.

11

12 \* **Corresponding author and address:** Mohamed Abdel-Mohsen, Ph.D. Assistant Professor, The  
13 Wistar Institute, Philadelphia, PA, USA, 19104, E-mail: [mmohsen@wistar.org](mailto:mmohsen@wistar.org)

14

15 **Key Words:** SARS-CoV2; COVID-19; Microbial Translocation; Inflammation; Zonulin.

16 **ABSTRACT**

17 A disruption of the crosstalk between the gut and the lung has been implicated as a driver of  
18 severity during respiratory-related diseases. Lung injury causes systemic inflammation, which  
19 disrupts gut barrier integrity, increasing the permeability to gut microbes and their products. This  
20 exacerbates inflammation, resulting in positive feedback. We aimed to test whether severe  
21 Coronavirus disease 2019 (COVID-19) is associated with markers of disrupted gut permeability.  
22 We applied a multi-omic systems biology approach to analyze plasma samples from COVID-19  
23 patients with varying disease severity and SARS-CoV-2 negative controls. We investigated the  
24 potential links between plasma markers of gut barrier integrity, microbial translocation, systemic  
25 inflammation, metabolome, lipidome, and glycome, and COVID-19 severity. We found that  
26 severe COVID-19 is associated with high levels of markers of tight junction permeability and  
27 translocation of bacterial and fungal products into the blood. These markers of disrupted  
28 intestinal barrier integrity and microbial translocation correlate strongly with higher levels of  
29 markers of systemic inflammation and immune activation, lower levels of markers of intestinal  
30 function, disrupted plasma metabolome and glycome, and higher mortality rate. Our study  
31 highlights an underappreciated factor with significant clinical implications, disruption in gut  
32 functions, as a potential force that may contribute to COVID-19 severity.

## 33 INTRODUCTION

34 Coronavirus Disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome  
35 coronavirus 2 (SARS-CoV-2) infection, can manifest with diverse clinical presentations. While the  
36 majority of infected individuals exhibit asymptomatic or mild respiratory tract infection, a significant  
37 population face severe manifestations such as acute respiratory distress syndrome (ARDS), multi-organ  
38 failure, and death (1). A state of hyper-inflammation and hyperactivated immune responses,  
39 characterized by an ensuing cytokine storm and increased complement activation, has been associated  
40 with COVID-19 severity (1, 2). However, the pathophysiological mechanisms that contribute to these  
41 phenomena remain mostly unknown. Understanding these mechanisms is a crucial step in designing  
42 rational clinical and therapeutic strategies.

43 A disruption of the crosstalk between the gut and the lung has been implicated as a driver of severity  
44 during respiratory-related diseases, including ARDS (3, 4). Systemic inflammation caused by a lung  
45 infection or injury can lead to a disruption of the gut barrier integrity and increase the permeability to  
46 gut microbes and microbial products. This microbial translocation can exacerbate systemic inflammation  
47 and lung injury – resulting in positive feedback (3, 4). In addition, SARS-CoV-2 can directly infect gut  
48 cells (5), and viral infections of the gut cause changes in gut structure and breakdown of the epithelial  
49 barrier (6).

50 Even as microbial translocation impacts systemic inflammation directly, it may also impact it indirectly  
51 by modulating circulating levels of gut- and gut microbiota-associated products such as metabolites and  
52 lipids. Plasma metabolites and lipids can reflect the functional status of the gut and the metabolic  
53 activity of its microbiota (7). They also are biologically active molecules in their own right, regulating  
54 several immunological functions, including inflammatory responses (8). A third class of microbial  
55 products that can translocate from the gut is glycan-degrading enzymes. Glycans on circulating  
56 glycoproteins and antibodies (IgGs and IgAs) are essential for regulating several immunological  
57 responses, including complement activation (9). The glycan-degrading enzymes are released by several  
58 members of the gut microbiome and their translocation can alter the circulating glycome, leading to  
59 higher inflammation and complement activation (10). Indeed, altered glycosylation of plasma  
60 glycoproteins (including immunoglobulin G, IgG) has been associated with the onset and progression of  
61 inflammatory bowel disease (IBD) (11). Furthermore, modulation of the gut microbiota via fecal  
62 microbiota transplantation affects IgG and serum glycosylation (12).

63 Here, we aimed to examine whether severe COVID-19 is associated with plasma markers of disrupted  
64 gut functions. Towards this aim, we applied a multi-omic systems biology approach to analyze plasma  
65 samples from COVID-19 patients with varying disease severity and SARS-CoV-2 negative controls.

66

## 67 MATERIALS AND METHODS

68 **Study main cohort.** Main analyses were performed using plasma samples from 60 individuals tested  
69 positive for SARS-CoV-2 and 20 SARS-CoV-2 negative controls collected at Rush University Medical  
70 Center (RUMC). The 60 SARS-CoV-2 positives were selected to represent three disease states: 20 with  
71 mild symptoms (outpatients); 20 with moderate symptoms (inpatients hospitalized on regular wards);  
72 and 20 with severe symptoms (inpatients hospitalized in an intensive care unit (ICU)) (**Figure 1a**).  
73 Individuals were selected to have a median age between 52.5 to 58.5 years. There was no significant  
74 difference in age between groups (**Supplementary Figure 1**). The study cohort was also chosen to have  
75 a 35 to 60% representation of female gender per disease status group (**Supplementary Table 1**). Eight

76 participants of the cohort (two from the moderate group and six from the severe group) died from  
77 COVID-19 (**Supplementary Table 1**).

78 **Study validation cohort.** Key measurements (zonulin, LBP, and soluble CD14) were confirmed using  
79 plasma samples from an independent cohort of 57 individuals tested positive for SARS-CoV-2 and 18  
80 SARS-CoV-2 negative controls collected at RUMC. The 57 SARS-CoV-2 positives were selected to  
81 represent three disease states: 20 with mild symptoms (outpatients); 18 with moderate symptoms  
82 (inpatients hospitalized on regular wards); and 19 with severe symptoms (inpatients hospitalized in an  
83 ICU) (**Supplementary Table 2**).

84 **Ethics.** All research protocols of the study were approved by the institutional review board (IRB) at  
85 Rush University (20070905-IRB01; approved July-27-2020) and at the Wistar Institute. All human  
86 experimentation was conducted in accordance with the guidelines of the US Department of Health and  
87 Human Services and those of the authors' institutions.

88 **Measurement of plasma markers of tight junction permeability and microbial translocation.** Plasma  
89 levels of soluble CD14 (sCD14), soluble CD163 (sCD163), LPS Binding Protein (LBP), and FABP2/I-  
90 FABP were quantified using DuoSet ELISA kits (R&D Systems; catalog # DY383-05, # DY1607-05, #  
91 DY870-05, and # DY3078, respectively). The plasma level of zonulin was measured using an ELISA kit  
92 from MyBiosorce (catalog # MBS706368). Levels of occludin were measured by ELISA (Biomatik;  
93 catalog # EKC34871).  $\beta$ -glucan detection in plasma was performed using Limulus Amebocyte Lysate  
94 (LAL) assay (GlucateLL Kit, CapeCod; catalog # GT003). Plasma levels of Reg3A were measured by  
95 ELISA (RayBiotech; catalog # ELH-REG3A-1).

96 **Measurement of plasma markers of inflammation and immune activation.** Plasma levels of GM-CSF,  
97 IFN- $\beta$ , IFN- $\gamma$ , IL-10, IL-13, IL-1 $\beta$ , IL-33, IL-4, IL-6, TNF- $\alpha$ , Fractalkine, IL-12p70, IL-2, IL-21, IL-22,  
98 IL-23, IP-10, MCP-2, MIP-1 $\alpha$ , SDF-1 $\alpha$ , IFN- $\alpha$ 2 $\alpha$ , IL-12/IL-23p40, and IL-15 were determined using  
99 customized MSD U $\square$ PLEX multiplex assay (Meso Scale Diagnostic catalog# K15067L-2). Plasma  
100 levels of C-Reactive Protein (CRP), Galectin-1, Galectin-3, and Galectin-9 were measured using DuoSet  
101 ELISA kits (R&D Systems; catalog # DY1707, # DY1152-05, # DY2045, and # DY1154, respectively).  
102 Levels of Growth Differentiation Factor-15 (GDF-15) were measured by ELISA using GDF-15  
103 Quantikine ELISA Kit (R&D Systems; catalog # DGD150). Plasma levels of Myeloperoxidase (MPO),  
104 d-dimer, and C3a were measured by ELISA (Thermo Fischer; catalog # BMS2038INST, #  
105 EHDDIMER, #BMS2089, respectively).

106 **Untargeted measurement of plasma metabolites and lipids.** Metabolomics analysis was performed as  
107 described previously (13). Lipidomics analysis was performed as described previously (14).

108 **IgG isolation.** Bulk IgG was purified from plasma using Pierce Protein G Spin Plate (Thermo Fisher;  
109 catalog # 45204). IgG purity was confirmed by SDS gel.

110 **IgA isolation.** Bulk IgA was purified from IgG depleted plasma using CaptureSelect IgA Affinity  
111 Matrix (Thermo Fisher; catalog # 194288010). IgA was concentrated using Amicon<sup>®</sup> filters (Milipore  
112 catalog #UFC805024), and purity was confirmed by SDS gel.

113 **N-glycan analysis using capillary electrophoresis.** For both plasma and bulk IgG, N-glycans were  
114 released using peptide-N-glycosidase F (PNGase F) and labeled with 8-aminopyrene-1,3,6-trisulfonic  
115 acid (APTS) using the GlycanAssure APTS Kit (Thermo Fisher; catalog # A33952), following the  
116 manufacturer's protocol. Labeled N-glycans were analyzed using the 3500 Genetic Analyzer capillary  
117 electrophoresis system. Total plasma N-glycans were separated into 24 peaks (**Supplementary Table 3**)

118 and IgG *N*-glycans into 22 peaks (**Supplementary Table 4**). The relative abundance of *N*-glycan  
119 structures was quantified by calculating the area under the curve of each glycan structure divided by the  
120 total glycans using the Applied Biosystems GlycanAssure Data Analysis Software Version 2.0.

121 **Glycan analysis using lectin array.** To profile plasma total and IgA glycomes, we used the lectin  
122 microarray as it enables analysis of multiple glycan structures. The lectin microarray employs a panel of  
123 45 immobilized lectins with known glycan-binding specificity (lectins and their glycan-binding  
124 specificity are detailed in **Supplementary Table 5**). Plasma proteins or isolated IgA were labeled with  
125 Cy3 and hybridized to the lectin microarray. The resulting chips were scanned for fluorescence intensity  
126 on each lectin-coated spot using an evanescent-field fluorescence scanner GlycoStation Reader  
127 (GlycoTechnica Ltd.), and data were normalized using the global normalization method.

128 **Statistical analysis.** Kruskal-Wallis and Mann–Whitney U tests were used for unpaired comparisons.  
129 Spearman's rank correlations were used for bivariate correlation analyses. Severity correlation  
130 coefficient (SC *rho*) tested correlation versus patient groups with the severity groups quantified as  
131 follows: control=1, mild=2, moderate=3, severe=4. FDR for each type of comparison was calculated  
132 using the Benjamini–Hochberg approach within each data subset separately, and FDR<0.05 was used as  
133 a significance threshold. Principal Component Analysis was performed on log<sub>2</sub>-transformed z-scored  
134 data. Pathway enrichment analyses were done on features that passed significant SC *rho* at FDR<0.05.  
135 Enrichments for the metabolites were tested using QIAGEN's Ingenuity® Pathway Analysis software  
136 (IPA®, QIAGEN Redwood City, [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)) using the “Canonical Pathway” option.  
137 Enrichments for the lipids were done using LIPEA (<https://lipea.biotec.tu-dresden.de/home>) with default  
138 parameters. To explore biomarkers that could distinguish clinical outcome (hospitalization vs. non-  
139 hospitalization), a specific set of microbial translocation variables were identified among those with  
140 FDR<0.05. Variables for the multivariable logistic model were selected from the identified specific set  
141 of biomarkers using the Lasso technique with the cross-validation (CV) selection option by separating  
142 data in 5-fold. Due to the exploratory nature of this study with a moderate sample size, variable selection  
143 was determined using 100 independent rounds runs of CV Lasso with minimum tuning  
144 parameter lambda. The markers that were selected 80 or more times from 100 runs were used as a final  
145 set of variables in our model. The ability of the final logistic model was assessed by AUC with a 95%  
146 confidence interval. Statistical analyses were performed in R 4.0.2 and Prism 7.0 (GraphPad).

147

## 148 **RESULTS**

149 **Characteristics of the study main cohort and study overview.** We collected plasma samples from 60  
150 individuals testing positive for SARS-CoV-2 (by RT-PCR) and 20 SARS-CoV-2 negative controls. The  
151 60 SARS-CoV-2 positive individuals were selected to represent three disease states: 20 with mild  
152 symptoms (outpatients); 20 with moderate symptoms (inpatients hospitalized on regular wards); and 20  
153 with severe symptoms (inpatients hospitalized in an intensive care unit (ICU)) (**Figure 1a**). Individuals  
154 were selected to have a median age between 52.5 to 58.5 years. There was no significant difference in  
155 age between groups (**Supplementary Figure 1**). The study cohort was also chosen to have a 35 to 60%  
156 representation of female gender per disease status group (**Supplementary Table 1**). Samples from  
157 hospitalized patients (moderate and severe groups) were collected at the time of diagnosis when the  
158 patient was admitted (**Supplementary Table 1**). Eight individuals of the cohort (two from the moderate  
159 group and six from the severe group) died from COVID-19 (**Supplementary Table 1**). The plasma  
160 samples from all individuals in this cohort were used in a multi-omic, systems biology approach that  
161 measured: markers of tight junction permeability and microbial translocation using ELISA and Limulus  
162 Amebocyte Lysate assays; inflammation and immune activation/dysfunction markers using ELISA and

163 multiplex cytokine arrays; untargeted metabolomic and lipidomic analyses using mass spectrometry  
164 (MS); and plasma glycomes (from total plasma glycoproteins, isolated immunoglobulin G (IgG), and  
165 isolated immunoglobulin A (IgA)) using capillary electrophoresis and lectin microarray (**Figure 1a** and  
166 **Supplementary Table 6**).

167 ***Severe COVID-19 is associated with high levels of markers of tight junction permeability and***  
168 ***microbial translocation.*** We first asked whether severe COVID-19 is associated with differences in  
169 plasma markers of tight junction permeability and microbial translocation. We measured the plasma  
170 levels of eight established drivers and markers of intestinal barrier integrity (**Supplementary Table 6**).  
171 We found that severe COVID-19 is associated with high levels of zonulin (**Figure 1b**). Zonulin  
172 (haptoglobin 2 precursor) is an established mediator of tight junction permeability in the digestive tract,  
173 where higher levels of zonulin drive increases in tight junction permeability (15, 16). Notably,  
174 hospitalized individuals with higher plasma levels of zonulin were more likely to die compared to  
175 hospitalized individuals with lower levels of zonulin (**Figure 1c**).

176 These higher levels of zonulin could enable the translocation of microbes and their products from the gut  
177 into the blood, including parts of the cell wall of bacteria and fungus (17, 18). To test this supposition,  
178 we measured plasma levels of common bacterial and fungal markers. Exposure to bacterial endotoxin  
179 can be determined by measuring plasma lipopolysaccharide (LPS) binding protein (LBP). LBP is an  
180 acute-phase protein that binds to LPS to induce immune responses (19). Indeed, we observed high levels  
181 of LBP in individuals with severe COVID-19 compared to individuals with mild COVID-19 or controls  
182 (**Figure 1d**). We also found higher levels of  $\beta$ -glucan, a polysaccharide cell wall component of most  
183 fungal species and a marker of fungal translocation (20), in individuals with severe COVID-19  
184 compared to those with mild COVID-19 or controls (**Figure 1e**). In addition, there were significantly  
185 higher levels (FDR=0.025) of the tight junction protein occludin in the severe group compared to  
186 controls (data not shown). There also was a strong trend (FDR = 0.051) toward higher levels of the  
187 protein 3-alpha (REG3 $\alpha$ ), a marker of intestinal stress, comparing the severe and mild groups (data not  
188 shown). We did not observe high levels of intestinal fatty-acid binding protein (I-FABP), a marker of  
189 enterocyte apoptosis, suggesting that the high levels of tight junction permeability and microbial  
190 translocation are not associated with enterocyte death.

191 These high levels of tight junction permeability and microbial (both bacterial and fungal) translocation  
192 are expected to lead to microbial-mediated myeloid inflammation. Indeed, levels of soluble CD14  
193 (sCD14; monocyte inflammation marker) (**Figure 1f**) and myeloperoxidase (MPO; neutrophil  
194 inflammation marker) (**Figure 1g**) were significantly higher during severe COVID-19 compared to mild  
195 and control groups. Levels of soluble CD163 (sCD163) were also higher significantly (FDR=0.04) in  
196 the severe group compared to controls (data not shown). These data suggest that COVID-19 severity and  
197 mortality are associated with plasma markers of higher tight junction permeability and higher  
198 translocation of bacterial and fungal products to the blood.

199 ***Microbial translocation is linked to systemic inflammation.*** Higher levels of microbial translocation  
200 should lead to higher systemic inflammation. We measured the levels of 31 markers of systemic  
201 inflammation (**Supplementary Table 6**), including: 23 cytokines and chemokines (such as IL-6, IL-1 $\beta$ ,  
202 MCP-1, IP-10, and TNF $\alpha$ ), markers of inflammation and thrombogenesis (such as C-reactive protein  
203 (CRP) and D-dimer), a marker of complement activation (C3a), a marker of oxidative stress (GDF-15),  
204 and three immunomodulatory galectins (galectin-1, -3, and -9). As anticipated, the levels of many of  
205 these markers were higher in patients with severe COVID-19 compared to patients with mild COVID-19  
206 or controls (**Figure 2a-left**). In particular, we observed higher levels of several cytokines and  
207 inflammatory markers. In addition to the expected changes, we also observed significantly higher levels  
208 of the immunomodulatory lectins, galectin-3 (**Figure 2b**) and galectin-9 (**Figure 2c**). Levels of Gal-9

209 were higher in the plasma of hospitalized patients who eventually died compared to survivors (**Figure**  
210 **2d**). Last, notable dysregulations were observed in levels of C3a (**Figure 2e**; indicative of complement  
211 activation) and GDF-15 (**Figure 2f**; indicative of oxidative stress), with the levels of GDF-15 higher in  
212 deceased hospitalized patients compared to survivors (**Figure 2g**).

213 Next, we examined the correlations between the markers of intestinal barrier integrity (zonulin) or  
214 microbial translocation (LBP and  $\beta$ -glucan) and the 31 markers of systemic inflammation and immune  
215 activation. As shown in **Figure 2a-right**, higher levels of zonulin, LBP, or  $\beta$ -glucan were strongly  
216 positively correlated with higher levels of many of the markers of systemic inflammation and immune  
217 activation, including IL-6 (**Figure 2h-i**). These data suggest that the potential disruption of the gut  
218 barrier integrity and microbial translocation during severe COVID-19 is associated with systemic  
219 inflammation. Our results do not imply that microbial translocation is the primary trigger of this  
220 inflammation, as it is likely that many pathophysiological pathways are involved in inflammation during  
221 COVID-19. However, the robust literature indicating that microbial translocation can fuel inflammation  
222 is consistent with our findings.

223 *Severe COVID-19 is associated with a plasma metabolomic profile that may reflect disrupted gut*  
224 *function.* A second set of factors that may reflect the functional state of the gut and its microbiota are  
225 the plasma metabolites. Importantly, many of these are biologically active molecules that can directly  
226 impact immunological and inflammatory responses. We performed untargeted metabolomic analysis  
227 (using LC-MS/MS). Within the 80 plasma samples, we identified a total of polar 278 metabolites. We  
228 observed a significant metabolomic shift during severe COVID-19 (**Figure 3a**, a list of the top 50  
229 dysregulated metabolites is in **Supplementary Figure 2**). Indeed, in principal component analysis of the  
230 full metabolomic dataset, the first component was able to completely distinguish controls (and mild  
231 patients) from those with severe disease. Pathway analysis of the COVID-19-dysregulated metabolites  
232 showed disruption in tRNA charging, citrulline metabolism, and several other amino acid (AA)  
233 metabolic pathways (**Figure 3b**, the top 10 dysregulated metabolic pathways are shown; **Supplementary Table 7**  
234 shows the top 50 dysregulated metabolic pathways with FDR<0.05). Importantly, changes in AA metabolism,  
235 including citrulline, arginine, methionine, and tryptophan (see **Figure 3b**) can influence the AA-  
236 metabolizing bacterial communities and disrupt the gut-microbiome immune axis (21). AA are absorbed and  
237 metabolized by enterocytes and gut microbiota. Consumption of AA by the gut microbiome is important for  
238 bacterial growth and is involved in the production of key microbiome-related metabolites (21).  
239

240 Next, we focused on 50 of the metabolites (out of the total of 278) that are known to be associated with  
241 the function of the gut and its microbiota (**Supplementary Table 8** lists the 50 metabolites and their  
242 references). Levels of most of these gut-associated plasma metabolites (35 out of 50) were dysregulated  
243 during severe COVID-19 compared to mild disease or controls (**Table 1** and **Figure 3c**). Within this  
244 metabolic signature of COVID-19-associated gut dysfunction is citrulline, which is also identified as a  
245 top metabolic pathway dysregulated by severe COVID-19 (**Figure 3b**). Citrulline is an amino acid  
246 produced only by enterocytes and an established marker of gut and enterocyte function (22). Its levels  
247 are significantly lower during severe COVID-19 (**Figure 3d**). Also, within this metabolic signature is  
248 succinic acid, a marker of gut microbial dysbiosis, whose levels are higher during severe COVID-19  
249 (**Figure 3e**).

250 Notable differences were also observed in several metabolites involved in the catabolism of the AA  
251 tryptophan (**Figure 3b, c**). Higher levels of tryptophan catabolism, indicated by high levels of  
252 kynurenine and low levels of tryptophan (i.e., the [Kyn/Trp] ratio), is a marker of gut microbial  
253 dysbiosis (23). Indeed, we observed a higher [Kyn/Trp] ratio in individuals with severe COVID-19 than  
254 in those with mild disease or controls (**Figure 3f**). Furthermore, lower levels of tryptophan and higher

255 levels of kynurenic acid were associated with mortality among hospitalized COVID-19 patients (**Figure**  
256 **3g-h**). Together, these data indicate that a metabolic signature associated with severe COVID-19 is  
257 compatible with disrupted gut functions and dysregulated gut-microbiome axis. However, it is  
258 important to note that many of these metabolic pathways are multi-faceted and can also reflect  
259 dysregulations in multiple-organ systems.

260 *Plasma metabolomic markers of COVID-19-associated gut dysfunction associate with higher*  
261 *inflammation and immune dysfunction.* As noted above, many plasma metabolites are bioactive  
262 molecules that can directly impact immunological and inflammatory responses. Therefore, we sought to  
263 identify links between the 35 dysregulated gut-associated plasma metabolites (**Table 1**) and the  
264 dysregulated markers of microbial translocation, inflammation, and immune activation (**Figure 2a**). We  
265 observed strong links between levels of the dysregulated gut-associated metabolites and levels of  
266 markers of microbial translocation (**Figure 4a**) as well as levels of inflammation and immune activation  
267 (**Figure 4b**). Notable correlations were observed between lower levels of citrulline and higher IL-6  
268 (**Figure 4c**), higher levels of succinic acid and higher IL-6 (**Figure 4d**), and higher [Kyn/Trp] ratio and  
269 higher IL-6 (**Figure 4e**). These data highlight the potential links between disrupted metabolic activities,  
270 especially those related to the gut and its microbiota, and systemic inflammation and immune  
271 dysfunction during COVID-19.

272 *Severe COVID-19 is associated with disrupted lipid metabolism.* Intermediary metabolites and sulfur-  
273 containing amino acids are potent modulators of lipid metabolism. Therefore, we performed lipidomic  
274 analysis and identified a total of 2015 lipids using untargeted MS. Similar to the plasma metabolome,  
275 the plasma lipidome shifted significantly during severe COVID-19 (**Figure 5a**). These 2015 lipids were  
276 divided into 24 lipids classes (**Supplementary Table 9**); out of these 24 classes, 16 were significantly  
277 (FDR<0.05) different in the moderate and severe COVID-19 groups (11 were lower whereas five were  
278 higher compared to the mild or control groups) (**Figure 5b**). Pathway analysis of this severe-COVID-  
279 19-associated lipidomic signature showed that glycerophospholipid and choline metabolism were the  
280 most significantly dysregulated pathways (**Figure 5c**). The gut microbiota is heavily involved in these  
281 two interconnected pathways (24). Gut microbial dysbiosis can alter the digestion and absorption of  
282 glycerophospholipids, leading to several diseases (25, 26).

283 It is also known that COVID-19 severity is linked to pre-existing cardiometabolic-associated diseases  
284 (27). Furthermore, COVID-19 itself can cause liver dysfunction (28). Indeed, many of the individuals in  
285 our main cohort with moderate and severe COVID-19 had diabetes and/or high blood pressure. We  
286 sought to examine whether these conditions contribute to our main findings. We examined the  
287 differences in the levels of zonulin, LBP,  $\beta$ -glucan, sCD14, and IL-6 between hospitalized patients  
288 (moderate and severe groups) who had diabetes or not (**supplementary Figure 3a**), or patients who had  
289 high blood pressure or not (**supplementary Figure 3b**). We did not observe any significant difference in  
290 the levels of these selected markers between these groups. However, the contribution of pre-existing  
291 metabolic conditions and post-infection intestinal and liver complications to the observed disrupted  
292 plasma profiles warrant further investigation.

293

294 *Severe COVID-19 is associated with altered plasma glycomes that are linked to inflammation and*  
295 *complement activation.* Finally, we examined plasma glycomes. It has been reported that translocation  
296 of glycan-degrading enzymes released by several members of the gut microbiome can alter circulating  
297 glycomes (10). Within the plasma glycome, glycans on circulating glycoproteins and antibodies (IgGs  
298 and IgAs) play essential roles in regulating several immunological responses, including complement  
299 activation (9). For example, galactosylated glycans link Dectin-1 to Fc $\gamma$  receptor IIB (Fc $\gamma$ RIIB) on the



300 surface of myeloid cells to prevent inflammation-mediated by complement activation (9). A loss of  
301 galactose decreases the opportunity to activate this anti-inflammatory checkpoint, thus promoting  
302 inflammation and complement activation, including during IBD (10). Indeed, IgG glycomic alterations  
303 associate with IBD disease progression, and IBD patients have lower IgG galactosylation compared to  
304 healthy controls (11).

305 We applied several glycomic technologies to analyze the plasma glycome (total plasma, isolated IgG,  
306 and isolated IgA). First, we used capillary electrophoresis to identify the *N*-linked glycans of total  
307 plasma glycoproteins and isolated plasma IgG (this identified 24 and 22 glycan structures, respectively;  
308 their names and structures are in **Supplementary Tables 3 and 4**). We also used a 45-plex lectin  
309 microarray to identify other glycans on total plasma glycoproteins and isolated IgA. The lectin  
310 microarray enables sensitive analysis of multiple glycan structures by employing a panel of 45  
311 immobilized lectins (glycan-binding proteins) with known glycan-binding specificity (**Supplementary**  
312 **Table 5** lists the 45 lectins and their glycan-binding specificities) (29).

313 We first observed significant (FDR<0.05) glycomic differences during severe COVID-19 in levels of  
314 IgA glycans, plasma *N*-glycans, plasma total glycans, and IgG glycans (**Figure 6a**). These changes are  
315 exemplified by an apparent loss of the anti-complement activation galactosylated glycans from IgG and  
316 total plasma glycoproteins (**Figure 6b-c**, respectively). When we examined the correlations between the  
317 plasma glycome and markers of tight junction permeability/microbial translocation or  
318 inflammation/immune activation (**Supplementary Figure 4**), as expected, we observed significant  
319 negative correlations (FDR<0.05) between levels of terminal galactose on IgG or plasma glycoproteins  
320 and markers of permeability/ translocation (**Figure 6d**) or markers of inflammation (**Figure 6e**). These  
321 data highlight the potential links between the disrupted plasma glycome and systemic inflammation  
322 during COVID-19.

323 ***Multivariable logistic models, using cross-validation Lasso technique, selected gut-associated***  
324 ***variables whose combination associates with the risk of hospitalization during COVID-19.*** Our data  
325 thus far support the hypothesis that gut dysfunction may contribute to COVID-19 severity. We sought to  
326 examine whether markers of tight junction permeability and microbial translocation (**Supplementary**  
327 **Table 6**) can distinguish between hospitalized COVID-19 patients (moderate and severe groups  
328 combined) and non-hospitalized individuals (mild and controls combined). We applied the machine  
329 learning algorithm Lasso (least absolute shrinkage and selection operator) regularization to select  
330 markers with the highest ability to distinguish between the two groups. The analysis employed samples  
331 with complete data sets (n=79; one sample did not have complete data). Lasso selected zonulin, LBP,  
332 and sCD14 as the three markers to be included in a multivariable logistic regression model that  
333 distinguishes hospitalized from non-hospitalized individuals with area under the ROC curve (AUC) of  
334 99.23% (**Figure 7a-b**; 95% confidence interval: 98.1% -100%). This value was higher than the AUC  
335 values obtained from logistic models using each variable individually (**Table 2**). Next, we used the  
336 multivariable logistic model to estimate a risk score of hospitalization for each individual. We then  
337 examined the ability of these risk scores to classify hospitalized from non-hospitalized individuals. As  
338 shown in **Figure 7c**, the model correctly classified 97.5% of hospitalized (sensitivity) and 94.9% of non-  
339 hospitalized (specificity) individuals, with an overall accuracy of 96.2%. Furthermore, we examined the  
340 ability of the L-kynurenine/L-tryptophan [Kyn/Trp] ratio, an established marker of gut microbial  
341 dysbiosis described above, to distinguish hospitalized from non-hospitalized individuals. Logistic model  
342 showed that [Kyn/Trp] ratio alone can distinguish hospitalized from non-hospitalized with an AUC  
343 value of 91.9% (**Figure 7d**; 95% confidence interval: >85% -98.7%). These data raise the possibility  
344 that some of these markers may be able to predict the risk of disease progression if measured  
345 immediately after diagnosis. Markers of intestinal barrier permeability have been used as predictors of

346 multiple organ dysfunction during critical illness (30). Future longitudinal, controlled studies will be  
347 needed to assess this possibility.

348 ***Zonulin, LBP, and sCD14 plasma levels are higher during severe COVID-19 in an independent***  
349 ***validation cohort.*** Finally, we sought to confirm some of our key findings in an independent cohort of  
350 57 individuals tested positive for SARS-CoV-2 and 18 SARS-CoV2 negative controls. The 57 SARS-  
351 CoV-2 positives were selected to represent three disease states: 20 with mild symptoms (outpatients); 18  
352 with moderate symptoms (inpatients hospitalized on regular wards); and 19 with severe symptoms  
353 (inpatients hospitalized in an ICU) (**Supplementary Table 2**). We focused on three measurements,  
354 zonulin, LBP, and sCD14, as these three measurements together were able to distinguish hospitalized  
355 from non-hospitalized individuals in the main cohort (Figure 7a-c). We observed higher levels of  
356 zonulin, LBP, and sCD14 during severe COVID-19 in this validation cohort (**Figure 8a-c**).  
357 Furthermore, we validated our multivariable logistic model in Figure 7a-c using data from this  
358 validation cohort. A combination of zonulin, LBP, and sCD14 was able to distinguish hospitalized  
359 from non-hospitalized individuals in the validation cohort with AUC of 88.6% (95% confidence  
360 interval: 80.3% -96.8%; **Table 3**). This analysis further highlights the plausible link between severe  
361 COVID-19 and disrupted gut function.

362

## 363 **DISCUSSION**

364 We used a systems biology approach to provide multiple layers of evidence that severe COVID-19 is  
365 associated with markers of disrupted intestinal barrier integrity, microbial translocation, and intestinal  
366 dysfunction. These data highlight disruption in gut barrier integrity as a potential force that may  
367 contribute to COVID-19 severity. Our data are compatible with previous reports showed that severe  
368 COVID-19 is associated with bacterial translocation to the blood and increased levels of microbial-  
369 associated immune activation markers (31, 32). Our results do not imply that microbial dysbiosis and  
370 translocation are the primary triggers of severe COVID-19, as the complex clinical syndrome of severe  
371 COVID-19 likely embodies multiple pathophysiological pathways. Also, our *in vivo* analyses do not  
372 unequivocally demonstrate a causal relationship between gut dysfunction and COVID-19 severity.  
373 However, the robust literature indicating that a disrupted intestinal barrier and microbial dysbiosis and  
374 translocation fuel inflammation and disease severity during ARDS (3, 4) supports our hypothesis and is  
375 consistent with our findings.

376 SARS-CoV-2 infection can affect the gastrointestinal tract (GI) tract and cause GI symptoms (33).  
377 Recently, it has been suggested that the severity of GI symptoms (mainly vomiting and diarrhea)  
378 correlates inversely with COVID-19 severity (for unclear reasons) (34). On the other hand, our  
379 observations suggest that disruption in gut function and higher microbial translocation correlate  
380 positively with COVID-19 severity. These are not necessarily mutually exclusive findings, but rather  
381 indicate that the interplay between the gut and SARS-CoV2 infection in modulating disease severity is  
382 complex. The potential role of the gut should be further explored, in multiple cohorts and settings,  
383 longitudinally during different stages of infection, and using gut biopsies and stool samples. Also, it will  
384 be important to examine, in future studies, the location and extent of these potential barrier defects along  
385 the length of small and large intestine, using gut biopsies from infected patients and controls.

386 Intestinal disruption during SARS-CoV-2 infection could be caused directly, and/or indirectly. Directly,  
387 SARS-CoV-2 can infect gut cells (5); other viral infections of the gut can change gut structure and cause  
388 breakdown of the epithelial barrier (6). Indirectly, lung infection or injury leads to systemic  
389 inflammation (including a cytokine storm), which then disrupts gut barrier integrity, increasing the

390 permeability to gut microbes and microbial products. Whether the potential disruption of the gut barrier  
391 during severe COVID-19 is caused directly by infection and/or indirectly by systemic inflammation and  
392 cytokines is not known but warrant further investigations. Also, it will be important to examine the  
393 impact of this potential microbial translocation on immune cell functions both in the intestines and  
394 systemically.

395 Our data raise several critical questions, including are there long-term implications of the potential  
396 disrupted gut barrier and intestinal function in survivors of severe COVID-19? In survivors of SARS-  
397 CoV-1 infection, long-term health complications (including metabolic dysfunctions) were observed for  
398 many years after convalescence (35). HIV+ individuals also can suffer complications of gut microbial  
399 translocation for years after viral suppression (36) The current 'long-haulers' (37, 38) after severe  
400 COVID-19 may also be on a path towards long term consequences due to persistent, microbial  
401 translocation. Understanding the long-term implications of the potential disrupted gut function during  
402 severe COVID-19 should be a clinical priority. An accompanying priority should be to consider how to  
403 modify clinical practice to prevent or reduce gut disruption. Currently, for example, a large number of  
404 patients are receiving antibiotic therapy during their COVID-19 treatment (39). However, massive use  
405 of antibiotics can alter gut microbiota and gut function, leading to higher susceptibility to inflammatory  
406 disorders (40). Thus, for any clinical practices that alter the gut, their overall impact on disease course  
407 should be carefully considered.

408 Our study also reveals several potential therapeutic targets for severe COVID-19, including zonulin.  
409 Zonulin is an established modulator of the intestinal tight junctions (15). Microbial dysbiosis and  
410 translocation enhance zonulin release, which in turn induces tight junction permeability, leading to more  
411 microbial translocation. This microbial translocation triggers inflammation, which promotes further gut  
412 leakiness (17, 18). Increased intestinal permeability and serum zonulin levels have been observed during  
413 many inflammatory diseases, including Crohn's disease (41). Preventing zonulin-mediated increase in  
414 intestinal permeability by a zonulin receptor antagonist AT1001 (Iarazotide acetate) decreased the  
415 severity and incidence of several inflammation-associated diseases in pre-clinical and clinical studies  
416 (42-44). The high levels of serum zonulin we observed during severe COVID-19, which were associated  
417 with inflammation and mortality, raise the question of whether modulators of tight junction permeability  
418 (such as with AT-1001) can lessen COVID-19 severity.

419 Our data show a disruption in several multi-faceted metabolic pathways, some of which are linked to gut  
420 functions. Plasma citrulline levels were lower in both moderate and severe COVID-19 patients  
421 compared to the mild and control groups, and the citrulline metabolism and biosynthesis pathways were  
422 among the top metabolic pathways disrupted in severe COVID-19. Citrulline is an intermediate in  
423 arginine metabolism (45), and is an established marker of gut and enterocyte function (22, 46).  
424 Disrupted citrulline metabolism, as we observed during severe COVID-19, has been associated with  
425 microbial dysbiosis and dysregulated intestinal function (47). However, ACE2 blocking is an alternative  
426 explanation of the low levels of citrulline. ACE2 is required for the function of amino acid transporters  
427 (48). Thus, the binding of SARS-CoV-2 to ACE2 may reduce the functions of amino acid transporters,  
428 leading to the reduction of citrulline and other amino acids such as tryptophan. Additionally, plasma  
429 citrulline levels might be an indication of defects in liver and/or kidney functions (49). We also observed  
430 high levels of succinic acid and kynurenic acid. Both metabolites have been associated with intestinal  
431 microbial dysbiosis (23, 50). However, succinic acid has also been associated with mucosal hypoxia  
432 (50). To what extent the disruption of intestinal barrier integrity and microbial dysbiosis contribute to  
433 these disrupted metabolic pathways should be the subject of future studies. These studies will help us to  
434 better understand the interaction between the gut, intestinal microbiota, and amino acid metabolism

435 during COVID-19. This understanding might be critical to inform pharmaceutical and diet approaches to  
436 improve COVID-19 outcomes.

437 A significant strength of our multi-omics approach is its ability to uncover connections between severe  
438 COVID-19 and biomolecules of different classes. The carbohydrate structures (glycans) attached to  
439 circulating proteins, including antibodies, and their receptors (lectins) are increasingly being appreciated  
440 for their essential roles in a variety of immune functions. Among the glycobiological molecules  
441 regulated by severe COVID-19 are galectins (increasing) and galactosylated glycans on circulating  
442 glycoproteins (decreasing). Both may point to potential glycomic contributions to the severity of  
443 COVID-19. First, galectins (secreted, GalNAc-binding proteins) have emerged as significant modulators  
444 of cytokine expression by immune cells during several diseases, including viral infections (51).  
445 Importantly, small molecule inhibitors for galectins, especially for Gal-3, can reduce inflammation and  
446 cytokine release (52). Therefore, galectins represent potential therapeutic targets to reduce cytokine  
447 storm during COVID-19 (53).

448 Caveats of our study include the sample size and sampling of blood. As noted above, correcting for  
449 potential confounders (such as ethnicity) will require larger cohorts from varying geographic and  
450 demographic settings. Additional independent test sets and samples from non-COVID-19 hospitalized  
451 and ICU-admitted patients will also be needed. Longitudinal analyses will be required to examine the  
452 long-term implications of our findings and their potential value as prognostic biomarkers. Analysis of  
453 gut biopsies, stool, and bronchial lavage will be needed to determine the precise contributions of the gut-  
454 lung axis in COVID-19. Analyzing the impact of the potential microbial translocation during severe  
455 COVID-19 on particular immune cell (such as Th17) in the intestines and systemically, will be also  
456 needed. Furthermore, environmental differences in diet and social environment may impact intestinal  
457 inflammation, therefore, future studies to understand the potential impact of socioeconomic status on the  
458 potential link between microbial translocation and severe COVID-19 will be needed. Finally,  
459 mechanistic studies *in vitro* and in animal models of SARS-CoV2 infection will be needed to examine  
460 the direct versus the indirect impact of the infection on intestinal barrier integrity and function.

461 In summary, while this study was exploratory in nature, our data suggest: (1) severe COVID-19 is  
462 associated with markers of a) disrupted intestinal barrier integrity; b) higher microbial translocation; and  
463 c) gut dysfunction; (2) severe COVID-19 is associated with a dramatic shift in levels of several  
464 biologically active molecules, which likely contribute to disease severity by inducing inflammation. Our  
465 study is beginning to shed light on the potentially critical role of intestinal barrier integrity in the  
466 pathophysiology of severe COVID-19. By understanding these underappreciated underpinnings of  
467 COVID-19, this work may serve to identify biomarkers for risk stratification and build a foundation for  
468 developing strategies to prevent or reduce the severity of COVID-19.

## 469 FIGURE LEGENDS

470 **Figure 1. Severe COVID-19 is associated with an increase in markers of tight junction**  
471 **permeability and microbial translocation. (a)** An overview of the main cohort study design;  
472 moderate and severe patients were hospitalized; severe indicates patients in the intensive care  
473 unit. **(b)** Levels of plasma zonulin, are higher during moderate and severe COVID-19 compared  
474 to mild COVID-19 or controls. Kruskal–Wallis test was used for statistical analysis. False  
475 discovery rate (FDR) was calculated using the Benjamini-Hochberg method. Symbols in black  
476 indicate deceased. **(c)** Zonulin levels are higher in hospitalized COVID patients (n=40) who  
477 eventually died from COVID-19 (n=8) compared to survivors (n=32). Nominal *P*-value was  
478 calculated using the Mann–Whitney U test. **(d-g)** Levels of LBP **(d)**,  $\beta$ -Glucan **(e)**, sCD14 **(f)**,  
479 and MPO **(g)**, are higher during severe COVID-19 compared to mild COVID-19 or controls.  
480 Kruskal–Wallis test was used for statistical analysis. FDR was calculated using Benjamini-  
481 Hochberg method. Black dots indicate deceased.

482 **Figure 2. Markers of tight junction permeability and microbial translocation are associated**  
483 **with markers of systemic inflammation. (a left)** Heat-map depicting plasma levels of 23  
484 inflammation and immune activation/dysfunction markers whose levels are statistically  
485 (FDR<0.05) different between the four disease states. Statistical significance was determined  
486 using the Kruskal–Wallis test. FDR was calculated using Benjamini-Hochberg method. *SC rho* =  
487 coefficient of correlation with COVID-19 severity. Heat colors show standardized Z-scores  
488 across samples; red indicates upregulation, and blue indicates downregulation. **(a right)**  
489 Coefficients of correlation between zonulin, LBP, or  $\beta$ -Glucan and each of the 23 inflammation  
490 and immune activation/dysfunction markers. All red-colored correlations had statistical  
491 significance of FDR<0.05, whereas the grey-colored correlation was non-significant.  
492 Correlations were evaluated using Spearman's rank correlation tests, and FDR was calculated  
493 using the Benjamini-Hochberg method. **(b-d)** Levels of representative variables, galectin-3 (Gal-  
494 3) **(b)** and galectin-9 (Gal-9) **(c)**, were higher during severe COVID-19 compared to mild  
495 COVID-19 or controls, with levels of Gal-9 higher among deceased hospitalized patients  
496 compared to survivors **(d)**. **(e-g)** Levels of C3a **(e)** and GDF-15 **(f)** were higher during severe  
497 COVID-19 compared to mild COVID-19 or controls, with levels of GDF-15 higher among  
498 deceased hospitalized patients compared to survivors **(g)**. Kruskal–Wallis and Mann-Whitney  
499 tests were used for statistical analysis. FDR was calculated using Benjamini-Hochberg method.  
500 **(h-i)** Examples of correlations in **(a)** between LBP and IL-6 **(h)** or  $\beta$ -Glucan and IL-6 **(i)**.  
501 Spearman's rank correlation tests were used for statistical analysis. Black dots indicate deceased.

502 **Figure 3. Severe COVID-19 is associated with metabolic dysregulation. (a)** Principal  
503 component analysis (PCA) of the 278 metabolites identified in the plasma of the study cohort.  
504 Each symbol represents a study participant. **(b)** Ingenuity Pathway Analysis (IPA) of the plasma  
505 metabolites modulated between the disease states with FDR<0.05. The graph shows the top 10  
506 dysregulated metabolic pathways with FDR<0.05. Percentages beside each pathway represent  
507 the ratio of dysregulated metabolites among the total number of metabolites assigned to this  
508 particular pathway in IPA. **(c)** Volcano plots depicting plasma metabolites dysregulated in the  
509 moderate group compared to the mild group (left) or the severe group compared to the mild  
510 group (right). NS= non-significant. The gut-associated metabolites (from Table 1) are indicated  
511 by the larger symbols, and a selected set is identified by name. **(d-f)** As representative examples,  
512 levels of citrulline are lower **(d)**, levels of succinic acid are higher **(e)**, and the ratio between

513 kynurenine/tryptophan [Kyn/Trp] is higher (**f**) during severe COVID-19 compared to mild  
514 COVID-19 or controls. Kruskal–Wallis test was used for statistical analysis. FDR was calculated  
515 using Benjamini-Hochberg method. (**g-h**) For key metabolites in the tryptophan catabolism  
516 pathway, levels of tryptophan are lower (**g**), and levels of kynurenic acid are higher (**h**) in  
517 deceased COVID-19 hospitalized patients compared to survivors. Nominal *P*-value was  
518 calculated using the Mann–Whitney U test. Black dots indicate deceased.

519 **Figure 4. Metabolic markers of intestinal dysfunction are linked to microbial translocation**  
520 **and systemic inflammation.** Correlation heat-maps depicting the correlations between COVID-  
521 19-modulated, gut-associated metabolites, and (**a**) markers of tight junction permeability and  
522 microbial translocation or (**b**) markers of inflammation and immune dysfunction. *SC rho* =  
523 coefficient of correlation with COVID-19 severity. Red-colored correlations = significant  
524 positive correlations with  $FDR < 0.05$ , blue-colored correlations = significant negative  
525 correlations with  $FDR < 0.05$ , gray-colored correlations = non-significant ( $FDR > 0.05$ ). (**c-e**)  
526 Examples of the correlations between citrulline and IL-6 (**c**), succinic acid and IL-6 (**d**), or  
527 [Kyn/Trp] ratio and IL-6 (**e**). Spearman's rank correlation tests were used for statistical analysis.  
528 FDR was calculated using Benjamini-Hochberg method.

529 **Figure 5. Severe COVID-19 is associated with disrupted lipid metabolism.** (**a**) Principal  
530 component analysis (PCA) of 2015 lipids identified in the plasma of the study cohort. (**b**) The  
531 2015 identified lipids were assigned to 24 classes (Supplementary Table 5). Heat-map depicts the  
532 16 lipid classes dysregulated by severe COVID-19 ( $FDR < 0.05$ ). Statistical significance was  
533 determined using the Kruskal–Wallis test. FDR was calculated using Benjamini-Hochberg  
534 method. *SC rho* = coefficient of correlation with COVID-19 severity. Heat colors show  
535 standardized *Z*-scores across samples; red indicates upregulation, and blue indicates  
536 downregulation. (**c**) Lipid pathway analysis of the plasma lipids modulated between the disease  
537 states with  $FDR < 0.05$  was performed using LIPEA (Lipid Pathway Enrichment Analysis;  
538 <https://lipea.biotech.tu-dresden.de/home>). The graph includes all dysregulated pathways with  
539  $FDR < 0.05$ . Percentages beside each pathway represent the ratio of dysregulated lipids among the  
540 total number of lipids assigned to this particular pathway by LIPEA.

541 **Figure 6. Severe COVID-19 is associated with plasma glycomic dysregulations.** (**a**) Heat-  
542 map depicting glycans dysregulated by severe COVID-19 ( $FDR < 0.05$ ). Names of the glycan-  
543 binding lectins are provided in parentheses. Statistical significance was determined using the  
544 Kruskal–Wallis test. FDR was calculated using Benjamini-Hochberg method. *SC rho* =  
545 coefficient of correlation with COVID-19 severity. Heat colors show standardized *Z*-scores  
546 across samples; red indicates upregulation, and blue indicates downregulation. (**b-c**) Levels of  
547 terminal digalactosylated *N*-glycans in IgG (**b**) or total plasma glycoproteins (**c**) are lower during  
548 severe COVID-19 compared to mild COVID-19 or controls. Kruskal–Wallis test. FDR was  
549 calculated using Benjamini-Hochberg method. (**e-d**) Correlation heat-maps depicting the  
550 correlations between galactosylated *N*-glycans (rows) and markers of tight junction permeability  
551 and microbial translocation (**d**) or markers of inflammation and immune dysfunction (**e**). *SC rho*  
552 = coefficient of correlation with COVID-19 severity. Red-colored correlations = significant  
553 positive correlations with  $FDR < 0.05$ , blue-colored correlations = significant negative  
554 correlations with  $FDR < 0.05$ , and gray-colored correlations = non-significant. Spearman's rank  
555 correlation tests were used for statistical analysis. FDR was calculated using Benjamini-  
556 Hochberg method. Black dots indicate deceased.

557 **Figure 7. Logistic models using markers of tight-junction permeability and microbial**  
558 **translocation distinguish hospitalized from non-hospitalized individuals. (a-b)** The machine  
559 learning algorithm, Lasso (least absolute shrinkage and selection operator) regularization,  
560 selected three markers (zonulin, LBP, and sCD14) that, when combined, can distinguish  
561 hospitalized from non-hospitalized individuals. (a) The receiver operator characteristic (ROC)  
562 curve from the multivariable logistic regression model with the three variables combined. (b)  
563 feature importance plot. (c) Coefficients from the multivariable logistic model were used to  
564 estimate a hospitalization risk score for each individual and then tested for the ability of these  
565 scores to accurately classify hospitalized (n=40) from non-hospitalized (n=39; one sample did  
566 not have a complete dataset) individuals at an optimal cut-point. Squares represent individuals  
567 the model failed to identify correctly. (d) Logistic regression model using the L-kynurenine/L-  
568 tryptophan [Kyn/Trp] ratio is able to distinguish hospitalized from non-hospitalized individuals.  
569 ROC curve showing the area under the curve (AUC) is 91.3%.

570 **Figure 8. Validation of key measurements in an independent cohort.** Levels of plasma (a)  
571 zonulin, (b) LBP, and (c) sCD14 are higher during moderate and severe COVID-19 compared to  
572 mild COVID-19 or controls in an independent validation cohort. Kruskal–Wallis test was used  
573 for statistical analysis.

574

## 575 TABLES

576 **Table 1.** Levels of the 35 (out of 50) gut- and gut microbiota-associated plasma metabolites that  
577 are disrupted during COVID-19. Red indicates upregulation, blue indicates downregulation;  
578 color intensity indicates larger difference. Green indicates FDR<0.05; color intensity indicates  
579 lower FDR.

580 **Table 2.** Results of logistic regression models of tight junction permeability and microbial  
581 translocation markers for ability to distinguish hospitalized from non-hospitalized individuals.

582 **Table 3.** AUC values of the logistic regression model built with data from the main cohort and  
583 validated with data from the validation cohort.

584

585

## 586 SUPPLEMENTARY MATERIALS

587 **Supplementary Figure 1: Age was not significantly different between the groups in the main**  
588 **cohort.** Kruskal–Wallis test was used for statistical analysis

589 **Supplementary Figure 2: Top 50 metabolites dysregulated by COVID-19.** Heat-maps depicting the  
590 top 25 metabolites induced and the top 25 metabolites reduced by COVID-19 (FDR<0.05). Statistical  
591 significance was determined using the Kruskal–Wallis test. FDR was calculated using Benjamini-  
592 Hochberg method. SC *rho* = coefficient of correlation with COVID-19 severity. Heat colors show  
593 standardized Z-scores across samples; red indicates upregulation, and blue indicates downregulation.

594 **Supplementary Figure 3: Levels of key markers are not different between groups with different**  
595 **diabetes or blood pressure status. (a)** No = non-diabetic; Pre = Pre-diabetic; and Yes = diabetic.  
596 Statistical significance was determined using the Kruskal–Wallis test (ns = non-significant;  $P>0.05$ ). **(b)**  
597 No = not suffering from high blood pressure and Yes = suffering from high blood pressure. Statistical  
598 significance was determined using the Mann–Whitney U test (ns = non-significant;  $P>0.05$ ).

599 **Supplementary Figure 4: The COVID-19-associated plasma glycomic signatures are associated**  
600 **with microbial translocation and systemic inflammation.** Correlation heat-maps depicting the  
601 correlations between COVID-19 modulated plasma glycans and **(a)** markers of tight junction  
602 permeability and microbial translocation or **(b)** markers of inflammation and immune dysfunction. SC  
603 *rho* = coefficient of correlation with COVID-19 severity. Red-colored correlations = significant positive  
604 correlations with FDR<0.05, blue-colored correlations = significant negative correlations with  
605 FDR<0.05, and gray-colored correlations = non-significant correlations.

606 **Supplementary Table 1.** Demographic and clinical characteristics of the study cohort.

607 **Supplementary Table 2.** Demographic characteristics of the validation cohort.

608 **Supplementary Table 3.** The structures and names of *N*-glycans identified in plasma by capillary  
609 electrophoresis. These glycan structures can be grouped into 15 groups: bisecting GlcNAc (B group),  
610 sialic acid (non-sialylated (S0), mono-sialylated (S1), di-sialylated (S2), tri-sialylated and (S3), tetra-  
611 sialylated (S4), and total sialylated (ST)), galactose (agalactosylated (G0), mono-galactosylated (G1), di-  
612 galactosylated (G2), and total galactosylated (GT)), core fucose (FC group), branched fucose (FB  
613 group), high branched (HB group), and low branch (LB group).

614 **Supplementary Table 4.** The structures and names of *N*-glycans identified in IgG by capillary  
615 electrophoresis. These glycan structures were grouped into 9 groups, depending on the presence or  
616 absence of four key monosaccharides: bisecting GlcNAc (B group), sialic acid (mon-sialylated (S1), di-  
617 sialylated (S2), and total sialylated (ST)), terminal galactose (agalactosylated (G0), mono-  
618 galactosylated (G1), di-galactosylated (G2), and total galactose (GT)), and fucose (F group).

619 **Supplementary Table 5.** Lectins used in the 45-plex lectin microarray and their glycan-binding  
620 specificity.

621 **Supplementary Table 6:** A list of plasma markers measured in this study.

622 **Supplementary Table 7:** Top 50 metabolic pathways disrupted by severe COVID-19.

623 **Supplementary Table 8:** List of the gut-associated and gut microbiota-associated metabolites detected  
624 in our study using untargeted LC-MS/MS (50 of the 278 metabolites identified in plasma).



625 **Supplementary Table 9.** The two thousand fifteen lipids identified in this study were assigned to 24  
626 lipid classes.

627 **ACKNOWLEDGMENTS**

628 This study is supported by a supplement to the NIH R01 DK123733 (R01 DK123733-01S1) for M.A-M,  
629 A.L, and A.Ke and R24 AA026801- 02S1 for A.Ke. M.A-M is also supported by The Foundation for  
630 AIDS Research (amfAR) impact grant # 109840-65-RGR, NIH grants (R01 AG062383, R01NS117458,  
631 R21 AI143385, R21 AI129636, and R21 NS106970), and the Penn Center for AIDS Research (P30 AI  
632 045008). The Wistar Proteomics and Metabolomics Shared Resource is supported in part by NIH  
633 Cancer Center Support Grant CA010815. The Thermo Q-Exactive HF-X mass spectrometer was  
634 purchased with NIH grant S10 OD023586. We would like to thank Rachel E. Locke, Ph.D., for  
635 providing comments.

636

637 **AUTHOR CONTRIBUTIONS**

638 M.A-M, A.L, and A.Ke conceived and designed the study. L.B.G. carried out the majority of  
639 experiments. H.D., X.Y, H.W, Q.L, and A.Ko performed all bioinformatics and biostatistical analyses.  
640 M.D. ran the lectin array experiments. C.S.P reviewed and selected gut-associated metabolites. N.F.Z,  
641 R.A.B, M.W.S, CBF, A.Ke, and A.L selected study participants and interpreted data. A.R.G, N.G, and  
642 H.T performed metabolic and lipidomic analyses. L.B.G. and M.A-M wrote the manuscript, and all  
643 authors edited it.

644

645 **COMPETING INTERESTS STATEMENT**

646 Authors have no competing interests.

647 **REFERENCES**

- 648 1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. 2020. Clinical Characteristics of  
649 Coronavirus Disease 2019 in China. *N Engl J Med* 382:1708-1720.
- 650 2. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. 2020.  
651 Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* 181:1036-  
652 1045 e9.
- 653 3. Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. 2018. The role of the lung  
654 microbiota and the gut-lung axis in respiratory infectious diseases. *Cell Microbiol* 20:e12966.
- 655 4. Dickson RP, Singer BH, Newstead MW, Falkowski NR, Erb-Downward JR, Standiford TJ, et al.  
656 2016. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory  
657 distress syndrome. *Nat Microbiol* 1:16113.
- 658 5. Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. 2020. SARS-  
659 CoV-2 productively infects human gut enterocytes. *Science* doi:10.1126/science.abc1669.
- 660 6. Turner JR. 2009. Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol*  
661 9:799-809.
- 662 7. Mayneris-Perxachs J, Fernandez-Real JM. 2020. Exploration of the microbiota and metabolites  
663 within body fluids could pinpoint novel disease mechanisms. *FEBS J* 287:856-865.
- 664 8. Davaatseren M, Hwang JT, Park JH, Kim MS, Wang S, Sung MJ. 2013. Poly-gamma-glutamic  
665 acid attenuates angiogenesis and inflammation in experimental colitis. *Mediators Inflamm*  
666 2013:982383.
- 667 9. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. 2012. Anti-  
668 inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB  
669 and dectin-1. *Nat Med* 18:1401-6.
- 670 10. Cao Y, Rocha ER, Smith CJ. 2014. Efficient utilization of complex N-linked glycans is a  
671 selective advantage for *Bacteroides fragilis* in extraintestinal infections. *Proc Natl Acad Sci U S*  
672 *A* 111:12901-6.
- 673 11. Simurina M, de Haan N, Vuckovic F, Kennedy NA, Stambuk J, Falck D, et al. 2018.  
674 Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel  
675 Diseases. *Gastroenterology* 154:1320-1333 e10.
- 676 12. Monaghan TM, Pucic-Bakovic M, Vuckovic F, Lee C, Kao D, Human Glycome P. 2019.  
677 Decreased Complexity of Serum N-glycan Structures Associates with Successful Fecal  
678 Microbiota Transplantation for Recurrent *Clostridioides difficile* Infection. *Gastroenterology*  
679 157:1676-1678 e3.
- 680 13. Li J, Agarwal E, Bertolini I, Seo JH, Caino MC, Ghosh JC, et al. 2020. The mitophagy effector  
681 FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells. *Sci*  
682 *Signal* 13.
- 683 14. Alicea GM, Rebecca VW, Goldman AR, Fane ME, Douglass SM, Behera R, et al. 2020.  
684 Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell  
685 Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. *Cancer Discov* 10:1282-  
686 1295.
- 687 15. Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, et al.  
688 2009. Identification of human zonulin, a physiological modulator of tight junctions, as  
689 preheptoglobin-2. *Proc Natl Acad Sci U S A* 106:16799-804.
- 690 16. Fasano A. 2011. Zonulin and its regulation of intestinal barrier function: the biological door to  
691 inflammation, autoimmunity, and cancer. *Physiol Rev* 91:151-75.
- 692 17. El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa GV, et al. 2002. Host-dependent  
693 zonulin secretion causes the impairment of the small intestine barrier function after bacterial  
694 exposure. *Gastroenterology* 123:1607-15.

- 695 18. Wood Heickman LK, DeBoer MD, Fasano A. 2020. Zonulin as a potential putative biomarker of  
696 risk for shared type 1 diabetes and celiac disease autoimmunity. *Diabetes Metab Res Rev*  
697 36:e3309.
- 698 19. Muta T, Takeshige K. 2001. Essential roles of CD14 and lipopolysaccharide-binding protein for  
699 activation of toll-like receptor (TLR)2 as well as TLR4 Reconstitution of TLR2- and TLR4-  
700 activation by distinguishable ligands in LPS preparations. *Eur J Biochem* 268:4580-9.
- 701 20. Morris A, Hillenbrand M, Finkelman M, George MP, Singh V, Kessinger C, et al. 2012. Serum  
702 (1->3)-beta-D-glucan levels in HIV-infected individuals are associated with  
703 immunosuppression, inflammation, and cardiopulmonary function. *J Acquir Immune Defic*  
704 *Syndr* 61:462-8.
- 705 21. Ma N, Ma X. 2019. Dietary Amino Acids and the Gut-Microbiome-Immune Axis: Physiological  
706 Metabolism and Therapeutic Prospects. *Comprehensive Reviews in Food Science and Food*  
707 *Safety* 18:221-242.
- 708 22. Fragkos KC, Forbes A. 2018. Citrulline as a marker of intestinal function and absorption in  
709 clinical settings: A systematic review and meta-analysis. *United European Gastroenterol J* 6:181-  
710 191.
- 711 23. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, et al. 2013.  
712 Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan  
713 catabolism. *Sci Transl Med* 5:193ra91.
- 714 24. Zhao M, Jiang Z, Cai H, Li Y, Mo Q, Deng L, et al. 2020. Modulation of the Gut Microbiota  
715 during High-Dose Glycerol Monolaurate-Mediated Amelioration of Obesity in Mice Fed a High-  
716 Fat Diet. *mBio* 11.
- 717 25. Liang W, Huang Y, Tan X, Wu J, Duan J, Zhang H, et al. 2019. Alterations Of  
718 Glycerophospholipid And Fatty Acyl Metabolism In Multiple Brain Regions Of Schizophrenia  
719 Microbiota Recipient Mice. *Neuropsychiatr Dis Treat* 15:3219-3229.
- 720 26. Eehalt R, Wagenblast J, Erben G, Lehmann WD, Hinz U, Merle U, et al. 2004.  
721 Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis  
722 patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. *Scand J*  
723 *Gastroenterol* 39:737-42.
- 724 27. Belanger MJ, Hill MA, Angelidi AM, Dalamaga M, Sowers JR, Mantzoros CS. 2020. Covid-19  
725 and Disparities in Nutrition and Obesity. *N Engl J Med* 383:e69.
- 726 28. Pawlotsky JM. 2020. COVID-19 and the liver-related deaths to come. *Nat Rev Gastroenterol*  
727 *Hepatol* 17:523-525.
- 728 29. Tateno H, Kuno A, Itakura Y, Hirabayashi J. 2010. A versatile technology for cellular glycomics  
729 using lectin microarray. *Methods Enzymol* 478:181-95.
- 730 30. Doig CJ, Sutherland LR, Sandham JD, Fick GH, Verhoef M, Meddings JB. 1998. Increased  
731 intestinal permeability is associated with the development of multiple organ dysfunction  
732 syndrome in critically ill ICU patients. *Am J Respir Crit Care Med* 158:444-51.
- 733 31. Arunachalam PS, Wimmers F, Mok CKP, Perera R, Scott M, Hagan T, et al. 2020. Systems  
734 biological assessment of immunity to mild versus severe COVID-19 infection in humans.  
735 *Science* 369:1210-1220.
- 736 32. Bowman ER, Cameron CMA, Avery A, Gabriel J, Kettelhut A, Hecker M, et al. 2021. Levels of  
737 Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 May Be Predictive of Death in  
738 Severe Coronavirus Disease 2019. *J Infect Dis* 223:805-810.
- 739 33. Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. 2020. Manifestations and prognosis of  
740 gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-  
741 analysis. *Lancet Gastroenterol Hepatol* 5:667-678.

- 742 34. Livanos AE, Jha D, Cossarini F, Gonzalez-Reiche AS, Tokuyama M, Aydillo T, et al. 2020.  
743 Gastrointestinal involvement attenuates COVID-19 severity and mortality. medRxiv  
744 doi:10.1101/2020.09.07.20187666:2020.09.07.20187666.
- 745 35. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. 2017. Altered Lipid Metabolism in Recovered  
746 SARS Patients Twelve Years after Infection. *Sci Rep* 7:9110.
- 747 36. Dinh DM, Volpe GE, Duffalo C, Bhalchandra S, Tai AK, Kane AV, et al. 2015. Intestinal  
748 microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. *J Infect*  
749 *Dis* 211:19-27.
- 750 37. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. 2020. Persistent Symptoms in  
751 Patients After Acute COVID-19. *JAMA* 324:603-605.
- 752 38. Anonymous. 2020. Meeting the challenge of long COVID. *Nat Med* 26:1803.
- 753 39. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. 2020. Epidemiological and clinical  
754 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive  
755 study. *Lancet* 395:507-513.
- 756 40. Knoop KA, McDonald KG, Kulkarni DH, Newberry RD. 2016. Antibiotics promote  
757 inflammation through the translocation of native commensal colonic bacteria. *Gut* 65:1100-9.
- 758 41. Sturgeon C, Fasano A. 2016. Zonulin, a regulator of epithelial and endothelial barrier functions,  
759 and its involvement in chronic inflammatory diseases. *Tissue Barriers* 4:e1251384.
- 760 42. Tajik N, Frech M, Schulz O, Schalter F, Lucas S, Azizov V, et al. 2020. Targeting zonulin and  
761 intestinal epithelial barrier function to prevent onset of arthritis. *Nat Commun* 11:1995.
- 762 43. Watts T, Berti I, Sapone A, Gerarduzzi T, Not T, Zielke R, et al. 2005. Role of the intestinal tight  
763 junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. *Proc*  
764 *Natl Acad Sci U S A* 102:2916-21.
- 765 44. Leffler DA, Kelly CP, Green PH, Fedorak RN, DiMarino A, Perrow W, et al. 2015. Larazotide  
766 acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized  
767 controlled trial. *Gastroenterology* 148:1311-9 e6.
- 768 45. Curis E, Nicolis I, Moinard C, Osowska S, Zerrouk N, Benazeth S, et al. 2005. Almost all about  
769 citrulline in mammals. *Amino Acids* 29:177-205.
- 770 46. Peters JH, Beishuizen A, Keur MB, Dobrowolski L, Wierdsma NJ, van Bodegraven AA. 2011.  
771 Assessment of small bowel function in critical illness: potential role of citrulline metabolism. *J*  
772 *Intensive Care Med* 26:105-10.
- 773 47. Kao CC, Cope JL, Hsu JW, Dwarkanath P, Karnes JM, Luna RA, et al. 2015. The Microbiome,  
774 Intestinal Function, and Arginine Metabolism of Healthy Indian Women Are Different from  
775 Those of American and Jamaican Women. *J Nutr* 146:706-713.
- 776 48. Camargo SMR, Vuille-Dit-Bille RN, Meier CF, Verrey F. 2020. ACE2 and gut amino acid  
777 transport. *Clin Sci (Lond)* 134:2823-2833.
- 778 49. Lau T, Owen W, Yu YM, Noviski N, Lyons J, Zurakowski D, et al. 2000. Arginine, citrulline,  
779 and nitric oxide metabolism in end-stage renal disease patients. *J Clin Invest* 105:1217-25.
- 780 50. Connors J, Dawe N, Van Limbergen J. 2018. The Role of Succinate in the Regulation of  
781 Intestinal Inflammation. *Nutrients* 11.
- 782 51. Wang WH, Lin CY, Chang MR, Urbina AN, Assavalapsakul W, Thitithanyanont A, et al. 2019.  
783 The role of galectins in virus infection - A systemic literature review. *J Microbiol Immunol*  
784 *Infect* doi:10.1016/j.jmii.2019.09.005.
- 785 52. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, et al. 2012.  
786 Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. *Am J Respir*  
787 *Crit Care Med* 185:537-46.
- 788 53. Caniglia JL, Guda MR, Asuthkar S, Tsung AJ, Velpula KK. 2020. A potential role for Galectin-3  
789 inhibitors in the treatment of COVID-19. *PeerJ* 8:e9392.


- 790 54. Gonthier MP, Cheynier V, Donovan JL, Manach C, Morand C, Mila I, et al. 2003. Microbial  
791 aromatic acid metabolites formed in the gut account for a major fraction of the polyphenols  
792 excreted in urine of rats fed red wine polyphenols. *J Nutr* 133:461-7.
- 793 55. Pellock SJ, Redinbo MR. 2017. Glucuronides in the gut: Sugar-driven symbioses between  
794 microbe and host. *J Biol Chem* 292:8569-8576.
- 795 56. Monagas M, Urpi-Sarda M, Sanchez-Patan F, Llorach R, Garrido I, Gomez-Cordoves C, et al.  
796 2010. Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and  
797 the bioactivity of their metabolites. *Food Funct* 1:233-53.
- 798 57. Zhitao H, Ailin S, Qingshuang W, Changyuan H, Liying S, Xianming S, et al. 2020. Research  
799 Square doi:10.21203/rs.3.rs-70833/v1.
- 800 58. Coman V, Vodnar DC. 2020. Hydroxycinnamic acids and human health: recent advances. *J Sci  
801 Food Agric* 100:483-499.
- 802 59. Skrzypecki J, Nieweglowska K, Samborowska E. 2020. Valeric Acid, a Gut Microbiota Product,  
803 Penetrates to the Eye and Lowers Intraocular Pressure in Rats. *Nutrients* 12.
- 804 60. Marhuenda-Munoz M, Laveriano-Santos EP, Tresserra-Rimbau A, Lamuela-Raventos RM,  
805 Martinez-Huelamo M, Vallverdu-Queralt A. 2019. Microbial Phenolic Metabolites: Which  
806 Molecules Actually Have an Effect on Human Health? *Nutrients* 11.
- 807 61. Selkirk J, Wong P, Zhang X, Pettersson S. 2014. Metabolic tinkering by the gut microbiome:  
808 Implications for brain development and function. *Gut Microbes* 5:369-80.
- 809 62. Farowski F, Els G, Tsakmaklis A, Higgins PG, Kahlert CR, Stein-Thoeringer CK, et al. 2019.  
810 Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance  
811 of Clostridiales. *Gut Microbes* 10:133-141.
- 812 63. Huang YY, Martinez-Del Campo A, Balskus EP. 2018. Anaerobic 4-hydroxyproline utilization:  
813 Discovery of a new glyceryl radical enzyme in the human gut microbiome uncovers a widespread  
814 microbial metabolic activity. *Gut Microbes* 9:437-451.
- 815 64. Rea K, Dinan TG, Cryan JF. 2016. The microbiome: A key regulator of stress and  
816 neuroinflammation. *Neurobiol Stress* 4:23-33.
- 817 65. Pan L, Han P, Ma S, Peng R, Wang C, Kong W, et al. 2020. Abnormal metabolism of gut  
818 microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia.  
819 *Acta Pharm Sin B* 10:249-261.
- 820 66. Molinero N, Ruiz L, Sanchez B, Margolles A, Delgado S. 2019. Intestinal Bacteria Interplay  
821 With Bile and Cholesterol Metabolism: Implications on Host Physiology. *Front Physiol* 10:185.
- 822 67. Arias N, Arboleya S, Allison J, Kaliszewska A, Higarza SG, Gueimonde M, et al. 2020. The  
823 Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and  
824 Its Modulation of Human Diseases. *Nutrients* 12.
- 825 68. Maekawa M, Maekawa M, Ushida K, Hoshi S, Kashima N, Ajisaka K, et al. 2005. Butyrate and  
826 propionate production from D-mannitol in the large intestine of pig and rat. *Microbial Ecology in  
827 Health and Disease* 17:169-176.
- 828 69. Utzschneider KM, Kratz M, Damman CJ, Hullar M. 2016. Mechanisms Linking the Gut  
829 Microbiome and Glucose Metabolism. *J Clin Endocrinol Metab* 101:1445-54.
- 830 70. Mathewson ND, Jenq R, Mathew AV, Koenigskecht M, Hanash A, Toubai T, et al. 2016. Gut  
831 microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-  
832 versus-host disease. *Nat Immunol* 17:505-513.
- 833 71. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. 2014. Bile acids and the gut microbiome. *Curr  
834 Opin Gastroenterol* 30:332-8.
- 835 72. Di Rienzi SC, Britton RA. 2020. Adaptation of the Gut Microbiota to Modern Dietary Sugars  
836 and Sweeteners. *Adv Nutr* 11:616-629.
- 837 73. Craft IL, Geddes D, Hyde CW, Wise IJ, Matthews DM. 1968. Absorption and malabsorption of  
838 glycine and glycine peptides in man. *Gut* 9:425-37.

- 839 74. Yasumoto K, Sugiyama K. 1980. Perturbation by Bestatin of Glycyl-L-leucine Absorption in  
840 Isolated Epithelial Cells from Rat Intestine. *Agricultural and Biological Chemistry* 44:1339-  
841 1344.
- 842 75. Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, et al. 2018. Impact of the Gut Microbiota on  
843 Intestinal Immunity Mediated by Tryptophan Metabolism. *Front Cell Infect Microbiol* 8:13.
- 844 76. Krautkramer KA, Fan J, Backhed F. 2020. Gut microbial metabolites as multi-kingdom  
845 intermediates. *Nat Rev Microbiol* doi:10.1038/s41579-020-0438-4.
- 846 77. Jain A, Li XH, Chen WN. 2019. An untargeted fecal and urine metabolomics analysis of the  
847 interplay between the gut microbiome, diet and human metabolism in Indian and Chinese adults.  
848 *Sci Rep* 9:9191.
- 849 78. Zhang L, Ouyang Y, Li H, Shen L, Ni Y, Fang Q, et al. 2019. Metabolic phenotypes and the gut  
850 microbiota in response to dietary resistant starch type 2 in normal-weight subjects: a randomized  
851 crossover trial. *Sci Rep* 9:4736.
- 852 79. Oliphant K, Allen-Vercoe E. 2019. Macronutrient metabolism by the human gut microbiome:  
853 major fermentation by-products and their impact on host health. *Microbiome* 7:91.
- 854 80. Kong J-Q. 2015. Phenylalanine ammonia-lyase, a key component used for phenylpropanoids  
855 production by metabolic engineering. *RSC Advances* 5:62587-62603.
- 856 81. Heianza Y, Ma W, DiDonato JA, Sun Q, Rimm EB, Hu FB, et al. 2020. Long-Term Changes in  
857 Gut Microbial Metabolite Trimethylamine N-Oxide and Coronary Heart Disease Risk. *J Am Coll*  
858 *Cardiol* 75:763-772.


859

# Figure 1


**a**




**b**




**c**




**d**



**e**



**f**



**g**






Figure 2




Figure 3




Figure 4







Figure 5






Figure 6







Figure 7



**c** Risk score combining Zonulin, LBP, and sCD14



**d** Logistic model using [Kyn/Trp] ratio





Figure 8



Validation cohort

